TABLE 4.

Diagnostic efficiencies of FR⁺ CTCs, CA19‐9, and their combination in differentiating patients with PC and pancreatic benign diseases

Method	Sensitivity	Specificity	AUROC (95% CI)	P
FR+ CTCs	0.867	0.833	0.837 (0.675‐0.999)	<.05
CA19‐9	0.733	1.000	0.911 (0.819‐1.000)	<.05
FR+ CTCs+CA19‐9	0.978	0.833	0.944 (0.840‐1.000)	<.001

Abbreviations: AUROC, area under the receiver‐operating characteristic curve; CA19‐9, carbohydrate antigen 19‐9; CI, confidence interval; FR⁺ CTCs, folate receptor‐positive circulating tumour cells; PC, pancreatic cancer.